Key features and details
- Mouse monoclonal [VU-1D9] to EpCAM (Alexa Fluor® 647)
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: Alexa Fluor® 647. Ex: 652nm, Em: 668nm
- Isotype: IgG1
Product nameAnti-EpCAM antibody [VU-1D9] (Alexa Fluor® 647)
See all EpCAM primary antibodies
DescriptionMouse monoclonal [VU-1D9] to EpCAM (Alexa Fluor® 647)
ConjugationAlexa Fluor® 647. Ex: 652nm, Em: 668nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human EpCAM. (Small cell lung carcinoma cell line H69).
- Flow Cyt: MCF7 cells.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.4
Preservative: 0.0975% Sodium azide
Concentration information loading...
Purification notesPurified antibody is conjugated with Alexa Fluor® 647 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Anti-EpCAM antibody [VU-1D9] (FITC) (ab112067)
- Anti-EpCAM antibody [VU-1D9] (PE) (ab112068)
- Anti-EpCAM antibody [VU-1D9] (PerCP/Cy5.5®) (ab157319)
- Anti-EpCAM antibody [VU-1D9] (ab187372)
- Anti-EpCAM antibody [VU-1D9] - BSA and Azide free (ab212579)
- Anti-EpCAM antibody [VU-1D9] (APC) (ab239288)
- Anti-EpCAM antibody [VU-1D9] (Biotin) (ab79079)
- Anti-EpCAM antibody [B29.1 (VU-1D9)] (FITC) (ab8666)
Our Abpromise guarantee covers the use of ab239273 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 4µl for 106 cells.
(or 100 μl of whole blood).
FunctionMay act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Tissue specificityHighly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.
Involvement in diseaseDefects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
Sequence similaritiesBelongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Cellular localizationLateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction.
- Information by UniProt
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab239273 has been referenced in 1 publication.
- Takao M & Takeda K Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry A 79:107-17 (2011). PubMed: 21246706